Maltodextrin

Summary

Maltodextrin (CHEMBL2107951) is a phase-3 clinical-stage unknown; indicated across 26 conditions including constipation disorder and atopic eczema.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 26 conditions
• Clinical trials: 309

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2107951
Name	Maltodextrin
Type	Unknown
Max phase	3

Also known as: Dextri-maltose, Fortical, Glucidex, Glucodry, Leppin, Maldex, Maldrin, Maltodextrin, Polycal, Star-dri, MALTODEXTRIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

26 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	3	MONDO:0002203	HP:0002019
atopic eczema	3	MONDO:0004980	EFO:0000274
irritable bowel syndrome	3	MONDO:0005052	EFO:0000555
ulcerative colitis	2	MONDO:0005101	EFO:0000729
Rotavirus infection	2	MONDO:0005194	EFO:0002622
metabolic dysfunction-associated steatotic liver disease	2	MONDO:0013209	EFO:0003095
diarrheal disease	2	MONDO:0001673	HP:0002014
central serous chorioretinopathy	2	MONDO:0018616	EFO:0009784
major depressive disorder	2	MONDO:0002009	MONDO:0002009
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
Parkinson disease	2	MONDO:0005180	MONDO:0005180
nosocomial infection	2	MONDO:0043544	MONDO:0043544
alcohol abuse	2	MONDO:0002046	MONDO:0007079
metabolic syndrome X	1	MONDO:0011565	EFO:0000195
autism	1	MONDO:0005260	EFO:0003758
pouchitis	1	MONDO:0005312	EFO:0003921
prediabetes syndrome	1	MONDO:0006920	EFO:1001121
heart failure	1	MONDO:0005252	EFO:0003144
graft versus host disease	1	MONDO:0013730	EFO:0004599

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 309.

Phase distribution

Phase	Trials
Not specified	241
PHASE2	26
PHASE3	15
PHASE4	9
PHASE2/PHASE3	5
PHASE1	5
PHASE1/PHASE2	4
EARLY_PHASE1	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05188222	PHASE4	NOT_YET_RECRUITING	Preoperative Maltodextrin’s Effect on Cardiac Function in Cardiac Surgery
NCT00770432	PHASE4	COMPLETED	Study Comparing PEG 3350 Laxative to Placebo in the Treatment of Occasional Constipation (Study CL2007-12)(P08216)
NCT00955500	PHASE4	COMPLETED	Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy
NCT01779765	PHASE4	UNKNOWN	The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)
NCT02280772	PHASE4	COMPLETED	Effect of Glucomannan Supplementation on Body Weight in Overweight and Obese Children
NCT02376270	PHASE4	COMPLETED	Pectin, Aging and Intestinal Barrier Function
NCT02622867	PHASE4	COMPLETED	Lactobacillus Plantarum 3547 Effects Over Inflammatory and Immunologic Markers
NCT03117322	PHASE4	COMPLETED	Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation
NCT05614362	PHASE4	COMPLETED	Channa Striatus Extract on Albumin and Hs-CRP ESRD
NCT06836024	PHASE2/PHASE3	NOT_YET_RECRUITING	A Trial of Actazin Versus PEG 3350 for Maintenance Therapy in Children With Constipation
NCT07062198	PHASE3	RECRUITING	Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer’s Disease
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT01151878	PHASE3	COMPLETED	Glucomannan for Childhood Functional Constipation.
NCT01265355	PHASE2/PHASE3	COMPLETED	Community Based Prevention of Rotavirus Gastroenteritis by a Functional Food Supplement
NCT01286376	PHASE3	UNKNOWN	Evaluating the Effectiveness of LACTOFOS in Constipated Patients
NCT01414517	PHASE3	UNKNOWN	Study to Prevent Radiation Induced Damage to Bowel Using a Prebiotic Enhanced Diet.
NCT01500941	PHASE3	COMPLETED	Probiotics in Adults: do They Improve Atopic Dermatitis?
NCT01525316	PHASE3	COMPLETED	Lactoferrin for Prevention of Sepsis in Infants
NCT01824667	PHASE3	COMPLETED	Effect of B-GOS on GI Discomfort in Healthy Adults
NCT01901042	PHASE2/PHASE3	COMPLETED	Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms
NCT02215330	PHASE2/PHASE3	UNKNOWN	A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
NCT02270268	PHASE3	COMPLETED	Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome
NCT02998931	PHASE3	COMPLETED	Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients
NCT03113240	PHASE3	COMPLETED	Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients
NCT04816071	PHASE2/PHASE3	WITHDRAWN	Essential Amino Acid Supplementation in Older Adult COVID-19 Patients
NCT06104917	PHASE3	COMPLETED	Effect of Maolactin on Gastrointestinal Tract (GIT) Health
NCT06436781	PHASE3	COMPLETED	Effect of Maolactin™ FMR on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population
NCT06440252	PHASE3	COMPLETED	Effectiveness of a Grape Seed Extract on Circulatory Measures in Healthy Adults
NCT06444763	PHASE3	COMPLETED	Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population
NCT03667404	PHASE2	ACTIVE_NOT_RECRUITING	Resistant Maltodextrin for Gut Microbiome in Parkinson’s Disease: Safety and Tolerability Study
NCT04373057	PHASE1/PHASE2	RECRUITING	Prebiotic Galacto-oligosaccharide and Acute GVHD
NCT05480696	PHASE2	RECRUITING	Soluble Fibre Supplementation in NAFLD
NCT05946083	PHASE2	RECRUITING	The Brain, the Bug, and the Binge: the Interplay Between Binge Drinking, Gut Microbiota, and Brain Functioning
NCT06584552	PHASE2	RECRUITING	LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)
NCT06798948	PHASE2	RECRUITING	Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improving Metabolic Associated Fatty Liver Disease : a Randomized Clinical Trial
NCT06852365	PHASE2	RECRUITING	Combined Oral Contraceptive Pill and Resistance Starch
NCT06853912	PHASE2	RECRUITING	Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
NCT06993428	PHASE2	NOT_YET_RECRUITING	A Trial With EMP16 in Preparation for Late Phase Studies
NCT07189585	PHASE2	NOT_YET_RECRUITING	Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis
NCT01004120	PHASE1/PHASE2	COMPLETED	Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).